SEC Company Response from BioPharmX Corp (CIK 0001504167) — May 7, 2021
BioPharmX Corp (CIK 0001504167)
Date: May 7, 2021 · CIK: 0001504167 · Accession: 0001104659-21-063155
AI Filing Summary & Sentiment
File numbers found in text: 333-255742
Show Raw Text
CORRESP
1
filename1.htm
Timber Pharmaceuticals, Inc.
110 Allen Road, Suite 401
Basking Ridge, NJ 07920
May 7, 2021
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Timber Pharmaceuticals, Inc. (the “Company”)
Registration Statement
on Form S-3 (File No. 333-255742)
Ladies and Gentlemen:
In accordance with Rule 461
under the Securities Act of 1933, as amended, the Company hereby requests that the above-referenced Registration Statement (the “Registration
Statement”) be declared effective by the Securities and Exchange Commission at 5:00 p.m., Eastern Time, on May 11, 2021, or as soon
as practicable thereafter.
Please call Steven M. Skolnick
of Lowenstein Sandler LLP at (973) 597-2476 to confirm the effectiveness of the Registration Statement or with any questions.
[Signature page follows.]
U.S. Securities and Exchange Commission
May 7, 2021
Page 2
Very truly yours,
TIMBER PHARMACEUTICALS, INC.
By:
/s/ John Koconis
Name:
John Koconis
Title:
Chief Executive Officer and Chairman of the Board of Directors
-2-